JMS-17-2

JMS-17-2 (CAS No.: 1380392-05-1) is a potent and selective small-molecule antagonist of the chemokine receptor CX3CR1, a receptor for fractalkine (CX3CL1) that plays a critical role in cell adhesion, migration, and survival signaling within the tumor microenvironment. Exhibiting inhibitory activity in the sub-nanomolar range, JMS-17-2 effectively disrupts CX3CR1-mediated signaling pathways, including the suppression of fractalkine-induced ERK phosphorylation in breast cancer cell models, indicating interference with downstream pro-survival and migratory signaling cascades. Functional studies demonstrate that blockade of CX3CR1 by JMS-17-2 impairs metastatic seeding and colonization processes, particularly in models of breast cancer, where CX3CR1 has been implicated in facilitating tumor cell homing to bone and other organs. In vivo investigations using xenograft mouse models further show that administration of JMS-17-2 reduces the establishment and progression of disseminated tumor cells, as well as the expansion of existing lesions in skeletal and visceral tissues. This compound is therefore widely utilized as a research tool for studying chemokine receptor biology, tumor metastasis mechanisms, and CX3CR1-driven signaling pathways, with experimental concentrations or dosing regimens varying according to specific study designs and objectives.